Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 476 | 80 | 388 |
| Samples | 247 | 57 | 186 |
| Peptides | 188 | 42 | 152 |
Function
PPP1R16A · Protein phosphatase 1 regulatory subunit 16A
Myosin light chain kinase and phosphatase (MLCP) complexes control the phosphorylation states of regulatory myosin light chains, which is crucial for muscle and intracellular movement. MLCPs typically contain a catalytic protein phosphatase 1 (PP1c) subunit, a myosin phosphatase targeting (MYPT) subunit, and another smaller subunit. The protein encoded by this gene represents an MYPT subunit, which is responsible for directing PP1c to its intended targets. However, while the phosphorylation of other MYPT members results in PP1c inactivation, phosphorylation of the encoded protein by protein kinase A results in PP1c activation. [provided by RefSeq, Jan 2020].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 188 amino-acid changes on canonical ENST00000435887 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PPP1R16A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PPP1R16A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 7/612 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Gastric Carcinoma | 1/74 1% | 27/1809 1% |
| Burkitts Lymphoma | 2/32 6% | 1/196 1% |
| Melanoma | 1/210 0% | 26/1899 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 20/1592 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 5/810 1% |
| Colorectal Carcinoma | 7/143 5% | 20/3239 1% |
| Meningioma | 1/3 33% | 1/252 0% |
| Neuroendocrine Tumour | 4/154 3% | 1/577 0% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 3/1390 0% |
| Ovarian Carcinoma | 4/109 4% | 2/998 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Other Solid Cancers | 1/94 1% | 6/1515 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Prostate Carcinoma | 3/13 23% | 2/2105 0% |
Mutation Distribution
Where PPP1R16A is mutated · all tissues, split by cell line vs tissue
How many mutations in PPP1R16A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 476 mutations in PPP1R16A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|